≡ MENU
Cell Therapies
Header5
Cell Therapies
Header4
Cell Therapies
Header1
Cell Therapies
Header2
Cell Therapies
Header3

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Dawn Driscoll as its new Chief Executive Officer. Dawn is highly experienced in the cellular therapy industry and has over 20 years experience in the biotechnology industry globally, with expertise in cell therapy, licensing, acquisitions and commercialisation. The Board of Cell Therapies and …
Read more

Melbourne, Australia 26 June 2017: Cell Therapies has been awarded $1,000,000 in funding by the Australian Government Department of Industry, Innovation and Science through the Global Innovation Linkages programme.  On 10 April 2017, CTPL was announced as one of the nine successful Australian businesses and research organisations to be granted Round 1 funding to collaborate …
Read more

Melbourne, Australia 20 February 2017: Cell Therapies commitment to, and excellence in, bringing innovative cellular therapies into clinical practise has been recognised with an IMAPAC Asia-Pacific Bioprocessing Excellence Award. Managing Director and  CEO Dr Tim Oldham accepted the award for “Best Bioprocessing Excellence in Australia (CMO Category)” at an awards ceremony in Singapore on 15 …
Read more

Melbourne, Australia, 11 October 2016: Cell Therapies Pty Ltd (CTPL) is pleased to announce that CEO and Managing Director Dr Tim Oldham has been elected to the Board of the Alliance for Regenerative Medicine (ARM) for 2017. AusBiotech CEO Glenn Cross said: “On behalf of the Regenerative Medicine Advisory Group (RMAG) and AusBiotech, I would …
Read more

ISCT 2016

August 19th, 2016

CT’s contribution to ISCT 2016 Representatives from Cell Therapies presented at ISCT Singapore on the following topics: Apheresis – Douglas Watson, Cell Therapy Specialist Initial Comparison of 3 apheresis platforms for supporting the collection of CD3+ cells for CAR-T production Flow Cytometry – Alex Rizzitelli, Cell Therapy Specialist Flow cytometry tools for characterisation of GMP …
Read more

Melbourne 8 Feb 2016: Cell collection via apheresis is the starting point for manufacture of many cellular therapies, including most immuno-therapies. The high patient-to-patient variability, coupled with the specialised skills needed for these collections mean manufacturers have to deal with significant variation in incoming cellular material. Manufacturers are only now coming to grips with the …
Read more

REFORM NEEDED TO FULFILL OUR BIOTECH POTENTIAL is an article by AusBiotech’s Chief Executive, Dr Anna Lavelle, published in Melbourne’s Herald Sun on the 25 September 2015.  Dr Lavelle’s article refers to a young and promising Australian biotech industry that “has potential to be our future”.  Cell Therapies is one of a number of examples …
Read more

Melbourne and Kuala Lumpur 30 Sep 2015: Cell Therapies Pty Ltd (CTPL) has today received official notification from the Malaysian Government and Malaysian Biotechnology Corporation (BiotechCorp) that its Malaysian subsidiary, Cell Therapies Malaysia Sdn Bhd (CTMSB) has been awarded BioNexus status having met the conditions of the letter of offer made in February. The BioNexus status confers a ten …
Read more

Cell Therapies’ Chief Scientific Officer, Dr Dominic Wall will participate in AusBiotech2015 as part of the Regenerative Medicine Forum. He is quoted today in an article by Sue Dunlevy highlighting the opportunities for improved cancer outcomes emerging from CAR-T research and the remaining challenges of manufacturing these patient specific therapies cost effectively. See the full …
Read more

Cell Therapies Pty Ltd has been profiled in Australian Biotechnology’s most recent edition featuring advanced manufacturing. As cellular therapies transform healthcare for many unmet medical needs, new manufacturing capacity with unique skills in just-in-time production systems integrated with clinical point of care will be critical. CTPL provides this enabling infrastructure and with our founding partner …
Read more